JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Home・Elenco Azioni・REVOLUTION Medicines Inc

REVOLUTION Medicines Inc

Chiusa

SettoreSettore sanitario

34.69 -1.14

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

34.11

Massimo

35.14

Metriche Chiave
By Trading Economics
Entrata	-19M -213M
EPS	-1.13
Margine di Profitto	-74.379
Dipendenti	616
EBITDA	-24M -237M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+94.67% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-659M 6.9B
Apertura precedente	35.83
Chiusura precedente	34.69

Notizie sul Sentiment di mercato

By Acuity

23%

77%

41 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Strong Bullish Evidence

40.67 / 41.96 Supporto e resistenza

REVOLUTION Medicines Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

11 ago 2025, 17:49 UTC

I principali Market Mover

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11 ago 2025, 17:18 UTC

I principali Market Mover

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11 ago 2025, 16:25 UTC

Utili

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11 ago 2025, 23:50 UTC

Discorsi di Mercato

Nikkei May Rise as Yen Weakens -- Market Talk

11 ago 2025, 23:42 UTC

Discorsi di Mercato

Global Energy Roundup: Market Talk

11 ago 2025, 23:42 UTC

Discorsi di Mercato

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11 ago 2025, 23:36 UTC

Discorsi di Mercato

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11 ago 2025, 23:32 UTC

Discorsi di Mercato

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11 ago 2025, 23:02 UTC

Discorsi di Mercato

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11 ago 2025, 20:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

11 ago 2025, 20:37 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11 ago 2025, 20:37 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Bakkt Holdings 2Q Rev $577.9M >BKKT

11 ago 2025, 20:37 UTC

Utili

Acquisizioni, Fusioni, Takeovers

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11 ago 2025, 20:22 UTC

Utili

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11 ago 2025, 20:22 UTC

Utili

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11 ago 2025, 20:22 UTC

Utili

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11 ago 2025, 20:22 UTC

Utili

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11 ago 2025, 20:22 UTC

Utili

Exodus Movement 2Q Rev $25.8M >EXOD

11 ago 2025, 20:14 UTC

Discorsi di Mercato

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11 ago 2025, 19:12 UTC

Discorsi di Mercato

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11 ago 2025, 18:56 UTC

Discorsi di Mercato

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11 ago 2025, 18:31 UTC

Discorsi di Mercato

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11 ago 2025, 17:43 UTC

Discorsi di Mercato

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11 ago 2025, 17:28 UTC

Discorsi di Mercato

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11 ago 2025, 17:16 UTC

Discorsi di Mercato

Commodity Longs Fall to 11-Month Low -- Market Talk

11 ago 2025, 16:42 UTC

Acquisizioni, Fusioni, Takeovers

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11 ago 2025, 16:27 UTC

Acquisizioni, Fusioni, Takeovers

BBVA Says Sabadell Offer Remains in Effect

11 ago 2025, 16:26 UTC

Acquisizioni, Fusioni, Takeovers

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11 ago 2025, 16:25 UTC

Acquisizioni, Fusioni, Takeovers

Banco de Sabadell Announced TSB Sale on July 1

11 ago 2025, 16:25 UTC

Acquisizioni, Fusioni, Takeovers

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Confronto tra pari

Modifica del prezzo

REVOLUTION Medicines Inc Previsione

Obiettivo di Prezzo

By TipRanks

94.67% in crescita

Previsioni per 12 mesi

Media 67.55 USD 94.67%

Alto 80 USD

Basso 37.91 USD

Basato su 10 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per REVOLUTION Medicines Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

10 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 10 che hanno fornito valutazioni azionarie a REVOLUTION Medicines Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

40.67 / 41.96Supporto e resistenza

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Sentiment

By Acuity

41 / 374 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo REVOLUTION Medicines Inc

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.